Belzutifan, an orally administered hypoxia-inducible factor-2α (HIF-2α) inhibitor, represents a significant therapeutic advancement in renal cell carcinoma (9). The gene discussed is EPAS1; the disease is hereditary clear cell renal cell carcinoma.